Latest Sustainability News

OncoSil Medical Ltd has launched an $8 million equity raising to fund the commercial expansion and clinical development of its targeted radiotherapy device for pancreatic cancer, aiming to capitalise on growing European market adoption and upcoming trial catalysts.

Lode Resources is progressing its high-grade silver, antimony, gold, and tin projects in Tasmania and New South Wales, highlighted by robust drilling results and promising metallurgical tests. The company is advancing towards resource estimation and pilot production at Montezuma while expanding exploration across multiple targets.

Lode Resources has appointed Keith Mayes as Managing Director to spearhead the Montezuma Silver and Antimony Project development, while Ted Leschke shifts focus to exploration strategy as Executive Director – Exploration.

Theta Gold Mines Limited has released a Revised Feasibility Study for its TGME Gold Mine Project in South Africa, projecting robust economics with a 13.1-year mine life and first gold production slated for early 2027.

Retail Food Group has refinanced its senior debt with a new $41.2 million facility to back its Enhance & Grow strategy, while updating earnings guidance amid challenging trading conditions.

1414 Degrees has achieved a key milestone with its SiNTL silicon anode material reaching 500 mAh/g, matching current commercial standards ahead of schedule and setting sights on 600 mAh/g within a year.

NRW Holdings has landed three major contracts worth approximately $270 million, reinforcing its footprint in mining and infrastructure projects across Western Australia. These wins highlight NRW’s expanding role in critical regional developments set to unfold over the next two years.

Matsa Resources has completed processing its second campaign of gold ore from the Devon Pit, producing 23 gold doré bars valued at approximately $25.2 million, with mining for Campaign 3 already underway.

Aroa Biosurgery’s latest business update reveals promising clinical outcomes from its Myriad trauma study and evolving reimbursement policies that could reshape its market position. The company also projects solid revenue growth for FY26, supported by strategic commercial initiatives.

Aroa Biosurgery reaffirms strong FY26 guidance, buoyed by favourable US Medicare reimbursement for Symphony and promising trauma study results for Myriad.

Xero Limited has outlined a bold AI strategy and detailed the integration of Melio to accelerate its US market growth, supported by new financial disclosures and a clear path to profitability.

Xero Limited reveals new AI product demonstrations and updates on Melio’s integration, reaffirming ambitious US growth and FY28 revenue targets.